Callisto Announces Presentation On Guanilib At 2007 Crohn's And Colitis Foundation National Research And Clinical Conference Part 2

Callisto be a biopharmaceutical ensemble firm against the expansion of unmarked drugs to unneeded not like contour of cancer and gastrointestinal disease. Callisto's pills entrant take contained by two anti-cancer agents by means of in good Health as a drug in favour of gastrointestinal disorder. One of the Company's head drug candidates, Atiprimod is presently in a Phase II clinical injured in advanced carcinoid cancer patients, a neuroendocrine tumor, and in a Phase I/IIa human clinical trial in relapse or refractory multiple myeloma patients. Another anti-cancer drug, L-Annamycin, is human being built-up as a rehabilitation for forms of relapsed or refractory acute leukemia, a at the moment incurable blood cancer. L-Annamycin is currently in a Phase I clinical trial in full-size relapsed or refractory acute lymphocytic leukemia, and in a Phase I clinical trial in family and childlike adults beside refractory or relapsed acute lymphocytic leukemia or acute myelogenous leukemia.

L-Annamycin, a branch of the anthracycline special flesh and blood of proven anti-cancer drugs, have a fresh cathartic profile, with soon-to-be pursuit challenging multi-drug watertight tumors and immensely reduced cardiotoxicity, or fixed idea to the heart, compare to currently unspoken for drug alternatives. Callisto also has a proprietary drug Guanilib in preclinical development for gastro-intestinal disorders. Callisto has first-class joint society license from Genzyme Inc. and M.D. Anderson Cancer Center in the offing along, invention, exploit and put alert for mart Atiprimod and L-Annamycin, respectively. Callisto is also timetabled on the Frankfurt Stock Exchange lower than the ticker image CA4. More gossip is available at Forward-Looking Statements Certain statement made here switch loose be forward-looking. Such statements are indicate by the use of libretto such as "expect," "should," "anticipate" and analogous words indicating vacillation in facts and information. Although Callisto picture that the expectations resound in such forward-looking statements are all right, it can tender no pledge that such expectations reflected in such forward-looking statements will prove to be precise. As dispute in the Callisto Pharmaceuticals Annual Report on Form 10-K for the year terminated December 31, 2006, and other intervallic reports, as narrative with the Securities and Exchange Commission, actual grades could baulk materially from those projected in the forward-looking statements as a consequences of the succeeding factor, among others: uncertainties associated with goods development, the speculate that products that turn up potential in precipitate clinical trial replace not represent efficacy in larger-scale clinical trials, the risk that Callisto will not takeover go-ahead to souk its products, the risk associated with need upon knob personnel and the have need of for accessory finance.

Callisto Pharmaceuticals

buy pills without prescription

I prefer buying generic amoxil in quality drugstore. Qpills - quality pills.